Technische problemen in CTIS: geen bijdrage bij herindiening van aanvragen voor klinische proeven
CTIS technical issues: no fee for resubmission of clinical trial applications Publication date 02/04...
Publisher
Belgium
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
CTIS technical issues: no fee for resubmission of clinical trial applications Publication date 02/04...
Source route
Continue on famhp.be
Leave the platform to read the original full article on the publisher site.
Source: FAMHP Belgium
Scope: Regulatory
Related coverage
More related coverage
[SHINSA]English translation of review report: Peripheral Rotablator PRO and Visual-ICE Cryoablation System (Partial Change Approval)
医薬品・医療機器・再生医療等製品の承認審査・安全対策・健康被害救済の3つの業務を行う組織。
Medicines Australia firmly oppose US tariffs on pharmaceuticals
Medicines Australia firmly oppose US tariffs on pharmaceuticals 3 April 2026 : Medicines Australia a...
FDA alerts consumers and pet owners of Silver Star Brand’s voluntary recall of homeopathic drug products
The Food and Drug Administration is alerting consumers and pet owners about a voluntary recall of ce...
FDA alerts consumers of Sprayology’s voluntary nationwide recall of homeopathic water-based medicines due to microbial contamination
FDA issues alert about a voluntary recall of all lots with expiration dates from October 2018 to Jul...